2026-01-01 - Analysis Report
Okay, here's a comprehensive analysis of Johnson & Johnson (JNJ) based on the data you provided.

**Company Overview:** Johnson & Johnson is a multinational corporation that develops and manufactures pharmaceuticals, medical devices, and consumer packaged goods.

**1. Return Rate Comparison (JNJ vs. S&P 500 (VOO))**

*   **JNJ Cumulative Return:** 59.46%
*   **VOO Cumulative Return:** 102.21%
*   **Divergence:** -42.7% (Relative Divergence: 27.8%)

**Analysis:** JNJ has significantly underperformed the S&P 500 over the period covered by the cumulative return data. The -42.7% divergence indicates a substantial difference in returns. The relative divergence of 27.8% suggests the current divergence is near the lower end of its historical range.

**Alpha, Beta Analysis:**

|            | CAGR  | MDD   | Alpha  | Beta  | Cap(B) |
|------------|-------|-------|--------|-------|--------|
| 2024-2026  | 59.0% | 79.6% | -46.0% | -0.0 | 499.5  |

**Analysis:** The data provided shows CAGR 59% with MDD 79.6% from 2024-2026. The negative Alpha of -46.0% means that the stock has underperformed relative to the benchmark (S&P 500) on a risk-adjusted basis. Beta close to zero (-0.0) suggests low volatility and minimal correlation with the overall market. The company market capitalization is nearly $500B.

**2. Recent Stock Price Fluctuations**

*   **Current Close:** 206.91
*   **Last Market:** Price: 207.34, Previous Close: 206.91, Change: 0.21
*   **5-day SMA:** 207.13
*   **20-day SMA:** 206.84
*   **60-day SMA:** 198.07

**Analysis:** The current price is slightly above the previous close, suggesting a small upward movement.  The 5-day and 20-day Simple Moving Averages are very close together and near the current price, indicating a period of price consolidation. The 60-day SMA is significantly lower, suggesting the stock has experienced an upward trend over the past two months.

**3. RSI, PPO, and Expected Return**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 61.81
*   **PPO:** -0.35
*   **Hybrid Signal:** cash_0%_Buy 90% of cash (1 shares - Safe - MRI:0.80) (Cash Ratio: 0% on 2025-12-03)
*   **Recent (20 days) Relative Divergence Change:** -1.1 (Negative - short-term decline)
*   **Expected Return (%):** -63.7%

**Analysis:**

*   The MRI indicates a 'High Investment Recommended,' though this should be considered with other data.
*   The RSI of 61.81 is nearing overbought conditions (typically above 70).
*   The PPO of -0.35 suggests the short-term moving average is slightly below the long-term moving average, hinting at a potential downtrend.
*   The Hybrid Signal suggests to buy the stock in general.
*   The negative change in relative divergence over the past 20 days confirms a recent short-term decline relative to the S&P 500.
*   The -63.7% expected return is concerning and suggests that, based on this analysis, long-term investment could result in a loss, relative to the S&P 500.

**4. Recent News & Significant Events**

*   **Halda Cancer Deal:** JNJ stock slipped after the $3.05B Halda cancer deal closed, but Barclays lifted its target price.
*   **Upside in 2026:** Some analysts see potential upside for JNJ stock in 2026.
*   **Institutional Investors:** Some institutional investors are increasing their stakes in JNJ, while others are selling (PineStone Asset Management).
*   **Analyst Opinions:** Wall Street analysts generally view JNJ as a good investment.
*   **Trefis Analysis:** Trefis provides an outlook on what to expect from JNJ stock.

**Analysis:** The news is mixed. The Halda deal closing caused a slight dip, but analyst target price increases and the general consensus of analysts suggest optimism. The institutional activity is also mixed, indicating different perspectives on the stock's future. The presence of both positive and negative headlines warrants a cautious approach.

**4-2. Analyst Opinions (Consensus / Targets / Recent Changes)**

*   **Consensus:** Buy (Mean: 2.16)
*   **Opinions:** 24
*   **Target Price:** Avg: 210.13 / High: 240.00 / Low: 155.00

**Analysis:** The analyst consensus is leaning towards a "Buy" rating, with a mean score of 2.16. The average target price of $210.13 suggests a small potential upside from the current price of around $207. However, the wide range between the high and low target prices ($240 vs. $155) indicates significant uncertainty among analysts.

**5. Recent Earnings Analysis**

| 날짜       | EPS  | 매출       |
|------------|------|------------|
| 2025-10-22 | 2.14 | 23.99 B$   |
| 2025-07-24 | 2.3  | 23.74 B$   |
| 2025-04-23 | 4.57 | 21.89 B$   |
| 2024-10-23 | 1.12 | 22.47 B$   |
| 2025-10-22 | 1.12 | 22.47 B$   |

**Analysis:** The table shows that the JNJ's revenues are relatively stable in the range of ~$22-24B. However, there is volatility of the EPS, ranging from $1.12 to $4.57.

**6. Financial Information (Revenue, Profitability, Capital)**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-09-30   | $23.99B    | 69.56%         |
| 2025-06-30   | $23.74B    | 67.87%         |
| 2025-03-31   | $21.89B    | 66.40%         |
| 2024-12-31   | $22.52B    | 68.35%         |
| 2024-09-30   | $22.47B    | 69.01%         |

**Capital and Profitability:**

| Quarter      | Equity     | ROE    |
|--------------|------------|--------|
| 2025-09-30   | $79.28B    | 6.50%  |
| 2025-06-30   | $78.47B    | 7.06%  |
| 2025-03-31   | $78.11B    | 14.08% |
| 2024-12-31   | $71.49B    | 4.80%  |
| 2024-09-30   | $70.16B    | 3.84%  |

**Analysis:**

*   **Revenue:** Revenue is relatively consistent, hovering around $22-24 billion per quarter.
*   **Profit Margin:** Profit margins are very high and consistently above 66%, indicating strong profitability.
*   **Equity:** Equity is growing steadily over time, reflecting the company's retained earnings and asset growth.
*   **ROE:** ROE fluctuates considerably.

**7. Comprehensive Analysis (Summary)**

Johnson & Johnson (JNJ) presents a mixed picture:

*   **Underperformance:** JNJ has significantly underperformed the S&P 500 in terms of cumulative return, and the negative Alpha confirms this underperformance on a risk-adjusted basis.
*   **Price Consolidation:** Recent stock price movements show a period of consolidation around the 207 level.
*   **Technical Indicators:** The MRI suggests a 'High Investment Recommended' despite the negative divergence, the RSI nearing overbought levels and the negative PPO suggests a potential downturn.
*   **News & Analyst Sentiment:** News is mixed, with some positive analyst views and institutional investment offset by deal-related dips and some institutional selling. Overall analyst sentiment is leaning toward a "Buy," but target prices vary widely.
*   **Financial Health:** JNJ exhibits strong and consistent revenue and high profit margins, but ROE has fluctuated and expected return is deeply negative.

**Conclusion:**

Based on the provided data, a cautious approach to investing in JNJ is warranted. While the company exhibits strong financial health, its underperformance relative to the S&P 500, the volatility of ROE, negative expected return, and mixed news headlines raise concerns. Investors should carefully weigh these factors and conduct further research before making an investment decision.



**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.